Clinical-Stage Biotech Valuation Assumptions

This question practices how to think about a biotech pipeline valuation instead of applying a standard company-wide multiple. A candidate needs to identify the operating and scientific assumptions that drive value, including how many drug candidates exist, what stage each one is in, what disease area or indication each targets, how long development may take, and how sales may grow after launch. It also tests whether the candidate understands why investors focus on peak revenue potential, the timing of clinical milestones, and the effect of patent expiry or loss of exclusivity on future cash flows.

Interviewers ask this type of question because clinical-stage biotech companies are highly uncertain and their value depends on forward-looking judgment rather than current earnings. Strong answers show that the candidate can break a pipeline into separate assets, think through approval and commercialization risk, and understand how operating assumptions translate into discounted cash flow and equity value.